When was DeepCyte founded?

DeepCyte was founded in 2026 and raised its 1st funding round within a year of its incorporation.

Where is DeepCyte located?

DeepCyte is headquartered in United States.

How many employees does DeepCyte have?

As of Jul 31, 2026, the latest employee count at DeepCyte is 9.

Is DeepCyte a funded company?

DeepCyte is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Apr 13, 2026.

When was the latest funding round of DeepCyte?

DeepCyte's latest funding was a $***** Seed round on Apr 13, 2026, with participation from 0 investor. Its primary sector is Biopharma Outsourcing. In United States, the Biopharma Outsourcing sector has seen $646M in funding in 2026 to date.

Where does DeepCyte rank among its competitors?

DeepCyte ranks 5th amongst 12 active competitors, only 1 of which is funded. DeepCyte, which secured $1.5M in Apr, 2026.

Who are the top competitors of DeepCyte?

DeepCyte's top competitors include Scantox, ILS and Essem Compliance. Among them, DeepCyte secured the most recent funding round in April, 2026.

DeepCyte - 2026 Company Profile, Funding & Competitors

DeepCyte is a seed company based in United States, founded in 2026. It operates as a Developer of artificial intelligence models predicting drug toxicity in cells. DeepCyte has raised $1.5M in funding. The company has 12 active competitors, including 1 funded and 3 that have exited. Its top competitors include companies like Scantox, ILS and Essem Compliance.

Company Details

Developer of artificial intelligence models predicting drug toxicity in cells. This technology utilizes single-cell metabolomics to identify metabolic changes within individual cells. By analyzing these shifts, the models detect potential toxicity and provide mechanistic insights into how compounds affect cellular functions. The approach focuses on identifying metabolic patterns to explain the biological causes of drug-induced damage. These tools assist in evaluating safety profiles during the development of pharmaceutical compounds.

Website: www.deepcyte.bio/
Email ID: *****@DEEPCYTE.BIO

Key Metrics

Founded Year

2026

Location

United States

Stage

Seed

Total Funding

$1.5M in 1 round

Latest Funding Round

Seed, Apr 13, 2026, $*****

Ranked

5^th among 12 active competitors

Employee Count

9 as on Jul 31, 2026

Similar Companies

Scantox & 10 more

View DeepCyte's full profile

DeepCyte has raised a total funding of $1.5M over 1 round.

Here is the list of recent funding rounds of DeepCyte:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 13, 2026	4578860	Seed	3202611	8821793	9859234	2449820

Access funding benchmarks and valuations. Sign up today!

View details of DeepCyte's funding rounds and investors

DeepCyte's employee count trend

DeepCyte has 9 employees as of Jul 26. Here is DeepCyte's employee count trend over the years:

Uncover DeepCyte's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of DeepCyte include Scantox, ILS and Essem Compliance. Here is the list of Top 10 competitors of DeepCyte, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Scantox 1977, Lille Skensved (Denmark), Early Stage	Laboratory focused on providing pharmacology, toxicology, and histopathology services	$6.29M	Impilo	44/100
2nd	ILS 1985, Morrisville (United States), Acquired	Provider of clinical research and regulatory services	-	HHS, Sier Capital	31/100
3rd	Essem Compliance 2018, Nagpur (India), Unfunded	Clinical research organization providing non-clinical testing services, including GLP-compliant studies, for the pharmaceutical and chemical industries	-	-	24/100
4th	Concateno 2015, Wynnum (Australia), Acquired	Provider of drug research and development services to biopharma sector	-	Marwyn Value Investors, Marwyn	24/100
5th	DeepCyte 2026, United States, Seed	Developer of artificial intelligence models predicting drug toxicity in cells	$1.5M	-	23/100
6th	ICCR-Roßdorf 1987, Rossdorf (Germany), Acquired	Provider of reliable and high-quality toxicological services	-	-	20/100
7th	LeyshonBanks Toxicology 2020, France, Unfunded	CRO offering services for toxicology studies	-	-	16/100
8th	ToxAlliance Unfunded	Provider of toxicology consulting services for pharmaceutical product development and regulatory compliance	-	-	16/100
9th	Labmatics Technosolutions 2019, Bengaluru (India), Unfunded	Provider of toxicology safety assessments and custom software development services	-	-	16/100
10th	Mammoth Capital Ventures 2017, Blue Ridge (United States), Unfunded	CRO focused on providing toxicology services	-	-	16/100